Korean J Clin Oncol.  2017 Jun;13(1):25-31. 10.14216/kjco.17003.

Human epidermal growth factor receptor 2 expression in gastric cancer patients treated with curative intent gastrectomy

• Kim MK
• Lee SE
• Sohn JS
• Choi IS
• Moon JI
• Yoon DS
• Chun KW
• Lee HY
• Sung NS
• Park SM
• Choi WJ

• KMID: 2387995
• DOI: http://doi.org/10.14216/kjco.17003

Abstract

PURPOSE
This study aimed to clarify the association between human epidermal growth factor receptor 2 (HER-2) status and the clinicopathologic factors of patients who underwent curative intent gastrectomy.
METHODS
From June 2011 to May 2015, curative intent gastrectomy was performed in 441 patients at Konyang University Hospital. Among them, we evaluated the HER-2 status in 113 patients. Data on clinicopathologic parameters such as age, sex, histological subtype, endoscopic Lauren classification, tumor location, size, presence of lymphovascular invasion, invasion depth, pathologic stage, HER-2 overexpression, recurrence and survival were obtained. In this study, pathological HER-2 intensity scores of 0, 1+, and 2+ were assumed to be negative, 3+ only was to be positive for overexpression.
RESULTS
In a total of 113 cases who underwent curative intent gastrectomy with HER-2 testing, 16 (14.2%) cases had positivity of HER-2 overexpression. HER-2 overexpression had significant associations with tumor stage (19.0% in I-IIIb vs. 2.9% in IIIc-IV, P=0.036). Survival analysis of HER2 overexpression has no significant difference.
CONCLUSION
In this study, HER-2 overexpression rate was 14.2% and patient tumor stage had significant association with HER-2 overexpression.

Keyword

HER-2; Gastric cancer

MeSH Terms

Classification
Epidermal Growth Factor*
Gastrectomy*
Humans*
Receptor, Epidermal Growth Factor*
Recurrence
Stomach Neoplasms*
Epidermal Growth Factor
Receptor, Epidermal Growth Factor